Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 145 No. 5152 (2015)

Interdisciplinary options for diagnosis and treatment of organic erectile dysfunction

  • Nicolas Diehm
  • Anne-Katrin Borm
  • Hong Hak Keo
  • Stephen Wyler
DOI
https://doi.org/10.4414/smw.2015.14268
Cite this as:
Swiss Med Wkly. 2015;145:w14268
Published
13.12.2015

Abstract

Erectile dysfunction (ED) is a frequently encountered symptom in primary care and may be a clinical challenge requiring intensive interdisciplinary collaboration. The pathogenesis of organic ED may frequently be multifactorial. However, vascular or endocrine disorders as well as drug treatments are among its leading causes.

More recently, ED has been identified as an important sentinel symptom for systemic cardiovascular disease.

The purpose of the present mini-review is to provide an interdisciplinary overview on current diagnostic and treatment modalities for patients suffering from ED.

References

  1. Aytac IA, Araujo AB, Johannes CB, Kleinman KP, McKinlay JB. Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal Massachussetts Male Aging Study. Soc Sci Med. 2000;51(5):771–8.
  2. Goldstein I. Male sexual circuitry. Working Group for the Study of Central Mechanisms in Erectile Dysfunction. Sci Am. 2000;283(2):70–5.
  3. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85.
  4. Jackson G. Prevention of cardiovascular disease by the early identification of erectile dysfunction. Int J Impot Res. 2008;20(Suppl 2):S9–14.
  5. Ghanem H, Shamloul R. An evidence-based perspective to commonly performed erectile dysfunction investigations. J Sex Med. 2008;5(7):1582–9.
  6. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.
  7. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–103.
  8. Christ-Crain M, Meier C, Huber P, Zimmerli L, Trummler M, Muller B. Comparison of different methods for the measurement of serum testosterone in the aging male. Swiss Med Wkly. 2004;134(13-14):193–7.
  9. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of A. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31.
  10. Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766–78.
  11. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019–25.
  12. Available from: Pocket Guide EndoDiabNet (Aarau – Basel – Lucerne): http://www.ksa.ch/public/pocketguide/pocket-guide.pdf.
  13. Jackson G. Problem solved: erectile dysfunction (ED) = early death (ED). Int J Clin Pract. 2010;64(7):831–2.
  14. Rogers JH, Goldstein I, Kandzari DE, Kohler TS, Stinis CT, Wagner PJ, et al. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012;60(25):2618–27.
  15. Evans MF. Lose weight to lose erectile dysfunction. Can Fam Physician. 2005;51:47–9.
  16. Borm A, Luescher S, Mueller B. Erste Behandlungsschritte bei neuentdecktem Diabetes mellitus. Swiss Med Forum. 2012;12:929–35.
  17. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.
  18. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280–93.
  19. Bolona ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20–8.
  20. Nigro N, Christ-Crain M. Testosterone treatment in the aging male: myth or reality? Swiss Med Wkly. 2012;142:w13539.
  21. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–96.
  22. Rogers JH, Rocha-Singh KJ. Endovascular therapy for vasculogenic erectile dysfunction. Curr Treat Options Cardiovasc Med. 2012;14(2):193–202.
  23. Wang TD, Lee WJ, Yang SC, Lin PC, Tai HC, Hsieh JT, et al. Safety and six-month durability of angioplasty for isolated penile artery stenoses in patients with erectile dysfunction: a first-in-man study. EuroIntervention. 2014;10(1):147–56.
  24. Leriche R. Des obliterations arterielle hautes (obliteration de la termination de l’aorte) comme cause de insufficances circulatoire des membres inferieurs. Bull Mem Soc Chir. 1923;49:1404.

Most read articles by the same author(s)